Conditions of optimal recombinant human FcRn protein performance should be determined experimentally by the investigator.
The neonatal Fc receptor (FcRn) is responsible for transporting maternal IgGs to fetus/newborns and maintaining the homeostasis of IgGs in adults. FcRn resembles class I major histocompatibility complex in structure, and is composed of a transmembrane heavy chain and an invariant β2 microglobulin. Changes in the affinity of IgGs to FcRn lead to changes in the half-life of engineered IgGs and Fc fusion proteins. Longer half-life of therapeutic antibodies means lower dose and longer interval between administering. For some diagnostic agents, including imaging or radio-labeled agents, a shorter half-life in circulation results in lower non-specific binding and decreased side effects. Therefore, studying the interaction of FcRn and therapeutic antibodies has direct clinical implications.
BP4095: Recombinant human FcRn protein
Source: HEK 293 cell-derived.
Recombinant human FcRn protein is the FcRn (Ala24 - Ser297) and B2M (β2 Microglobulin) fusion protein with Myc tag and His tag at the C-terminus.
Activity: Recombinant human FcRn protein binds to human IgG in a pH dependent manner.
Formulation: 0.2 μM filtered solution of 20 mM Hepes, 150 mM NaCl, pH 7.5.
Endotoxin Level: Less than 1 EU/ug of protein as determined by LAL method.
Shipping: The product is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
1 month from date of receipt, 2 to 8°C as supplied.
3 months from date of receipt, -20°C to -70°C as supplied.